C. May

发表

Congenital Lipodystrophies and Dyslipidemias

X. Prieur, B. Cariou, J. Magré, 2014, Current Atherosclerosis Reports.

Impact of protease inhibitors on circulating PCSK9 levels in HIV-infected antiretroviral-naive patients from an ongoing prospective cohort

C. Vigouroux, J. Capeau, A. Cohen, 2017, AIDS.

Thiazolidinediones partially reverse the metabolic disturbances observed in Bscl2/seipin-deficient mice

M. Lathrop, F. Matsuda, C. Mounier, 2013, Diabetologia.

Roux-en-Y gastric bypass, but not sleeve gastrectomy, decreases plasma PCSK9 levels in morbidly obese patients.

M. Krempf, S. Ledoux, B. Cariou, 2020, Diabetes & metabolism.

The SGLT2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model

F. Charpentier, X. Prieur, B. Staels, 2017 .

IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts

J. Eckel, K. Eckardt, C. May, 2007, Diabetologia.

Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?

B. Cariou, C. May, W. Dijk, 2018, Trends in Endocrinology & Metabolism.

Roux-en-Y gastric bypass reduces plasma cholesterol in diet-induced obese mice by affecting trans-intestinal cholesterol excretion and intestinal cholesterol absorption

M. Krempf, X. Prieur, M. Neunlist, 2018, International Journal of Obesity.

The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis

B. Balkau, G. Charpentier, P. Froguel, 2015, Diabetologia.

E 2 F 1 inhibits circulating cholesterol clearance by regulating Pcsk 9 expression in the liver

L. Fajas, Pierre-Damien Denechaud, B. Cariou, 2017 .

Circulating PCSK9 levels in acute coronary syndrome: Results from the PC-SCA-9 prospective study.

V. Probst, V. Letocart, C. Le May, 2017, Diabetes & metabolism.